

Q3 FY23 Investor Presentation


February 2023




Biocon 5.0



Biocon is a technology-enabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through highquality, affordable therapies that can lower costs, increase access and improve treatment outcomes.







Biocon at a Glance





Countries where our products are available*





100+ cGMP approvals from International regulatory agencies



15 of top 20 pharma companies served by service portfolio *



Rank #8 Among Top 10 Global Biotech Employers**



Manufacturing units*



* Numbers as of FY22, ** 2022 Ranking by Science Magazine, *** As per IQVIA MIDAS Oct'22 MAT, top 50 molecules by revenue

Building Biocon


Biocon: One Company, with multiple value propositions across its verticals



From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality & affordable healthcare products & services, globally







Generics : API & Formulations - Growth Levers



Strengths built over the years

- Expertise in fermentation technology, large scale chromatography & synthetic chemistry
- Leveraging in-house API to forward integrate and move up the value chain
- Balanced portfolio across therapeutic segments

Product Portfolio Expansion

- API Expanding portfolio beyond fermentation and synthetic molecules to peptides, high potent APIs
- Formulations Complex injectables, device dependent products, potent oral solids, modifiedrelease and extended-release oral solids
- Augmenting portfolio through in-licensing strategy

Capacities Additions & Expansion

- Immunosuppressants API (Visakhapatnam)
- Other Fermentation APIs (Bengaluru)
- Peptides (Bengaluru)
- Synthetic API (Hyderabad)
- Injectables (Bengaluru)

Business Development initiatives

- · Strategic partnerships with select customers
- Local manufacturing mandate opportunities in global markets - Technology transfer/ API supply / finished dosage formulations
- API: Expansion of business in key select markets
- Formulations: Expand commercial footprint beyond U.S, either directly or through partners

Other initiatives

- Continued focus on cost improvement and quality compliance
- De-risk critical intermediates sources
- Digital transformation initiatives to support key strategic priorities
- Focus on ESG initiatives like use of renewable energy, promoting gender diversity (incl. women in the shop-floor)



Generics : Our Key APIs and Formulations

APIs*

Therapeutic Area	Molecule	Therapeutic Area	Molecule	Therapeutic Are
	Apixaban		Mycophenolate Mofetil	
	Atorvastatin	Immunosuppressants	Mycophenolate Sodium	
	Dabigatran		Pimecrolimus	
	Fluvastatin		Sirolimus	Cardiovascular
	Ivabradine		Tacrolimus	
	Pravastatin	Oncology	Dasatinib	
Cardiovascular	Rivaroxaban		Everolimus	
			Lenalidomide	Oncology
	Rosuvastatin		Temsirolimus	
	Simvastatin	Peptides	Liraglutide	Immunosuppressa
	Lovastatin		Fingolimod	
	Sacubitril Na	Multiple Sclerosis	Teriflunomide	Multiple Sclerosis
	Valsartan Disodium		Anidulafungin	
	Dapagliflozin		Micafungin	
	Empagliflozin		Posaconazole	
	Linagliptin	Others	Orlistat	Others
Anti-Diabetics	Repaglinide	others	Deferasirox	
	Sitagliptin		Brinzolamide	
	Vildagliptin		Mirabegron	
	Pioglitazone		Fidaxomicin	

FORMULATIONS


Therapeutic Area	eutic Area Molecule		Dev. Markets: ex- US	MoW ¹
	Rosuvastatin Calcium		EU	
	Simvastatin			
	Atorvastatin			
Cardiovascular	Pravastatin			
	Labetalol HCI			
	Prazosin			
Oreclery	Everolimus		EU\$	
Oncology	Pemetrexed	TA [#]		
	Tacrolimus			
Immunosuppressants	Mycophenolic Sodium			
Multiple Sclerosis	Fingolimod			
	Aminocaproic acid (Antifibrinolytic)			
	Dapagliflozin (Anti Diabetic)	TA#		
04.00	Esomeprazole DR (Gastrointestinal)			
Others	Dorzolamide (Ophthalmic)			
	Posaconazole (Anti-Fungal)		UK, EU ^{\$}	
	Vigabatrin Oral Solution (CNS)			

* Filed DMFs | 1 MoW - Most of the World markets | \$Select EU countries | TA – Tentative approval

Launched Approved


Biosimilars Business at a Glance





Biosimilars: Unique, fully integrated capabilities from lab to market





Biosimilars: Leading global player with a strong track record of success



Built on a 40+ year legacy of cutting-edge science

- Invested >\$1B in biosimilars ahead of its peers to build expertise across multiple platforms and a differentiated portfolio including insulins, mAbs and fusion proteins
- In-house R&D, clinical and regulatory capabilities to develop
 high precision biosimilars for global markets
- Expertise in large scale manufacturing, across Drug Substance, Drug Product and Devices and among the Top 15 globally in biomanufacturing capacity
- Commercial reach in 100+ markets through a combination of direct presence¹, strategic partnerships and distributors


...with a strong track record in an attractive market

- Achieved many 'firsts' in the industry first to receive bTrastuzumab, bPegfilgrastim and interchangeable bGlargine approval in the US
- Commercialized products in key Advanced Markets, such as the US, EU, Japan and several Emerging Markets (e.g., India, Brazil, UAE, etc.)
- Backed by marquee investors including Tata Capital, True
 North, Goldman Sachs, ADQ and Viatris
- Biosimilars are an attractive market with FY22 addressable of \$21B², growing to \$70B in FY27²

Committed to enabling affordable access to high quality biosimilars globally

1 Through the acquisition of Viatris' biosimilars business | 2 Only includes products where there has been company reported sales; Biosimilar sales only included for companies that report the numbers

Biosimilars: Acquisition of Viatris' global biosimilars business



Transformational deal to create value for all stakeholders

Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars




Therapy Area	Oncology X	Immunology	Ophthalmology	Bone Health	Diabetes	Others	Vaccines
Approved or Commercial	PegfilgrastimTrastuzumab	AdalimumabEtanercept			 RHI Glargine U100		
	BevacizumabDenosumab	Ustekinumab	Aflibercept	Denosumab	Aspart		Several Infectiou
Late Stage ¹	Pertuzumab						Disease Vaccine e.g. Malaria
Early Stage ²	2 undisclosed assets	3 undisclosed assets			• Glargine U300	2 undisclosed assets	

New product launches planned almost every year through 2030

1. Clinical to BLA Review; 2. Pre-Clinical

Biosimilars: Portfolio offers multiple shots on goal to drive sustainable growth





Biocon Biologics' portfolio targets a ~US\$ 70 Billion addressable market by FY27

Note: Market size only includes products where there has been company reported sales; Biosimilar sales only included for companies that report the numbers

Novel Molecules : Itolizumab





Pushing to deliver impactful innovations in collaboration with Equillium Inc.

World's first novel humanized anti-CD6 monoclonal antibody	Acute Graft- Versus-Host Disease (GVHD)	 ✓ Pivotal Phase III Study initiated in Mar '22 for use in First-Line treatment of Acute GVHD; patient dosing initiated ✓ European Commission granted Orphan Drug Designation for treatment of aGVHD in Jul '21 ✓ Received Fast Track designation from the US FDA
<i>that selectively targets the CD6-</i> <i>ALCAM pathway</i> Biocon's second global 'lab to market' novel biologic after Nimotuzumab Launched in India in 2013 to treat	Systemic Lupus Erythematosus/ Lupus Nephritis (SLE/LN)	 ✓ Received Fast Track designation from the US FDA ✓ Given positive trends in Part A, expanded Part B portion of Phase 1b EQUALISE study to clinical centers in India ✓ Patient recruitment continues
chronic plaque psoriasis under the brand ALZUMAb [™] Licensed out rights to develop & commercialize in the U.S., Canada, Australia and New Zealand to U.Sbased biotechnology company, Equillium Inc. in 2017	Cytokine Release Syndrome treatment in 'Moderate to Severe' Acute Respiratory Distress Syndrome	 ✓ Repurposed for prevention & treatment of COVID-19 complications in India in 2020 ✓ Granted 'Restricted Emergency Use' approval in Sep '20
Option and Purchase Agreement entered between Equillium and Ono Pharmaceutical Co., Ltd, Japan, where Equillium has granted Ono the exclusive right to acquire its rights to itolizumab	Ulcerative Colitis	 ✓ Application for Phase 2 clinical trials in India for the treatment of ulcerative colitis using Itolizumab, approved by the DCGI ✓ Initiated Phase 2 clinical study of itolizumab in patients with ulcerative colitis in Dec '22



The precision of f	targeted therapies	The power of tumor modulators

50.5	BCA 101	 Lead product candidate, BCA101 (EGFR / TGF-β-trap) demonstrates tumor target engagement and clinical activity Monotherapy activity in difficult to treat post-pembro squamous lung cancer Activity in combination with pembro in checkpoint and cetuximab-refractory head and neck cancer (HNSCC) and anal canal cancer BCA101 + pembrolizumab combination dose expansion study currently enrolling in 1L HNSCC – achieved efficacy threshold for Stage 1 prior to completing enrollment
BCA101		
(Formerly FmAb2) Lead candidate <i>First-in-class EGFR / TGFβ-trap</i> <i>bifunctional antibody</i>	Organization	 Highly experienced management team, board of directors and advisory board \$82M raised in Seed/Series A from syndicate of dedicated biotech investors (Biocon ownership at 53%) Leveraging the Biocon and Syngene infrastructure to offer agility and deep experience in CMC/drug development
	Platform	 ✓ ToTeM[™] – leverages rational combinations to unleash the full potential of targeted tumor modulators ✓ Pragmatic antibody engineering and manufacturable IgG-like biologics ✓ Delivering 2 additional INDs in 2023-2024

*a US based clinical-stage biotechnology company. In Q4FY21, Biocon ceded control over the Board of Directors and Operations of Bicara to enable it to operate independently under a US based leadership team and raise funds to advance its development programs. As a result of this change, Bicara was classified as an Associate from a Subsidiary under IND-AS.

Research Services :

Syngene has capabilities spanning the value chain, facilitating integration





Development and Manufacturing business Development Services Manufacturing Services Image: Comparison of the service o




Manufacturing of small and large molecules for commercial supplies

cGMP-compliant facilities

State-of-the-art API manufacturing and biologics manufacturing facilities

Research Services (Syngene) : Key Growth Levers





Quarterly Highlights

Financial Highlights: Q3 FY23 (1/2)



Consolidated (in INR Cr.)	Q3 FY23	Q3 FY22	YoY %	
Total Revenue	3,020	2,223	36	Biosimilars +54% Research +23% Generics +18%
Core EBITDA ¹	1,069	715	49	
% Margin	36%	33%		
EBITDA	723	537	35	Net R&D spend at ₹337Cr, up ₹199 Cr vs Q3 FY22 Forex Loss of ₹44Cr vs gain of ₹19 Cr in Q3 FY22
% Margin	24%	24%		
Profit Before Tax (Before exceptional charge)	246	269	(9)	Increase in amortisation and interest expense related to the acquisition of Viatris' biosimilar business
% Margin	8%	12%		
Net Profit (Before exceptional charge)	140	187	(25)	Increase in minority interest due to dilution of shareholding in Biocon Biologics and Syngene
Net Profit Margin %	5%	8%		

¹ Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, licensing income and mark to market movement investments.

Financial Highlights: Q3 FY23 (2/2)



Consolidated (in INR Cr.)	Q3 FY23	Q3 FY22	YoY %	
Net Profit (before exceptional charge)	140	187	(25)	
Exceptional Items (net of tax and minority interest)	(182)	-		Exceptional items during Q3 FY23 : Primarily pertain to deal related expenses of the Viatris transaction
Net Profit /(loss) (Reported)	(42)	187		

Generics: Q3 FY23 Update

KEY HIGHLIGHTS



Revenue growth led by increased demand for Immunosuppressant APIs as well as Generic Formulations

Margins, compared to the previous year were muted due to continued pricing pressure in the US market

Signed a partnership agreement with Zentiva for commercialising Liraglutide in 30 European countries

Signed a long term strategic partnership in Brazil for the supply and techtransfer of a finished dose formulation immunosuppressant product

Issued a GMP Certificate of Compliance by the European Directorate for the Quality of Medicines & HealthCare (EDQM), for our API manufacturing facility in Bengaluru, following a GMP inspection of the site conducted in September 2022.

Validation of the immunosuppressant API facility in Visakhapatnam and peptide facility in Bengaluru expected to be completed by H1 FY24

In INR Cr	Q3 FY23	YoY %	
Revenue from operations	718	607	18
PBT	72	67	8
% of revenue	10%	11%	

Biosimilars: Q3 FY23 Update

KEY HIGHLIGHTS



Revenue growth of 54% driven by Viatris deal closure and steady growth in BBL-led business

R&D investments increased to ₹280 Crores; completed recruitment for bDenosumab and bUstekimnumab clinical trials

bPertuzumab entered Phase 1 trials, initiated interchangeability study for bAdalimumab

All products surpass 10% market share in US; bAdalimumab garners 18% and 10% market share in Germany and France, respectively

Eight new launches in Emerging Markets

CAPA plan submitted for bAspart and bBevacizumab; committed to closure of actions within stipulated timeline



In INR Cr	Q3 FY23	Q3 FY22	YoY %
Revenue from operations	1,507	981	54
Core EBITDA	663	363	83
% of revenue	44%	38%	
PBT (before exceptions)	102	124	(17)
% of revenue	7%	13%	

Novels : Q3 FY23 Update

KEY HIGHLIGHTS

Enrolment continues to ramp up in the pivotal Phase III clinical study of Itolizumab in patients with aGVHD* (EQUATOR study)

Patient enrolment also continues for the pivotal Phase 1b clinical study of Itolizumab for Lupus Nephritis (equalise study)

The Phase II trial underway in India for the clinical study of Itolizumab in patients with Ulcerative Colitis, patient dosing (Randomization) began in December,2022

Equillium has recently entered into an Option and Purchase Agreement with Ono Pharmaceutical Co., Ltd, Japan, where Equillium has granted Ono the exclusive right to acquire its rights to Itolizumab





Research Services: Q3 FY23 Update

KEY HIGHLIGHTS

Delivered positive performances in all divisions. Sustained growth in Research divisions - Discovery Services and the Dedicated Centers

Development Services growth primarily driven by repeat orders from existing clients and a growing number of collaborations with emerging biopharma companies

Syngene successfully completed the US Food and Drug Administration (US FDA), European Medicines Agency (EMA) and Medicines and Healthcare products Regulatory Agency (MHRA) regulatory audits for its biologics manufacturing facility

With the Good Manufacturing Practice (cGMP) certifications from the regulatory agencies in place, the Company is on track to execute manufacturing of drug substance at a commercial scale and progress its Biologics manufacturing services growth strategy



In INR Cr	Q3 FY23	Q3 FY22	YoY %
Revenue from operations	786	641	23%
PBT	140	128	9%
% of revenue	18%	20%	

Environment, Social, Governance

ESG: A Culture of Purpose, Ethics & Equity

Going beyond financials to have a positive impact

Our ESG Strategy Pillars

Ø

×.

\$

Improve access to high quality therapeutics to drive 'Patient Equity'

Build an empowering and inclusive workplace creating 'People Equity'

Adapting to a sustainable business operations for 'Environment Equity'


Operate with integrity, transparency and accountability ensuring 'Stakeholder Equity'

Enable underserved communities 'Social Equity'

Monitor Performance \rightarrow Improve Through Initiatives \rightarrow Report Outcomes

ecovadis and improved score to 52

in 2021.




SBiocon

Annexures

Biocon's Evolution: Our journey over the last 5 decades

Metamorphosis from manufacturer of enzymes to a vertically integrated bio-pharmaceutical player and global CRO & CDMO of global standing. Created tangible differentiators for sustainable growth with focus on research and innovation





With many firsts, Biocon is ahead of the curve

• 1 st Indian Life Sciences Company to get ISO 9001 Certification	 1st Clinical Research Service Organization in India established - Clinigene 	• 1 st company globally to get U.S. FDA approval for making Lovastatin API through innovative fermentation technology.	 1st company in the world to develop & commercialize Pichia -based rh-Insulin 	 1st Indian Company to launch a novel biologic, Nimotuzumab for head and neck cancer patients 	• 1 st anti-CD6 monoclonal antibody in the world, Itolizumab, commercialised in India
1993	2000	2001	2004	2006	2013
 1st company to introduce biosimilar Trastuzumab in the world 	 1st company from India to have a biosimilar approved in Japan 	 1st company globally to receive U.S. FDA approval for biosimilar Trastuzumab 	 1st company to launch Fulphila[™], biosimilar Pegfilgrastim in U.S. 	 1st company from India to have a biosimilar commercialized in the US 	• 1 st company to receive interchangeability designation for a biosimilar (insulin glargine) in the US
2014	2016	2017	2018	2018	2021

Safe Harbor Statement



Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

